Author

Mi Na Kim

h-index 14 View on Semantic Scholar

We have 2 of 50 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.

INTRODUCTION After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV. METHODS This retrospective, m...

Min-Ji Lee, Su-Bin Lim, J. Shim et al. · Hepatology International · 0 citations

Open access Aug 2026

The impact of alcohol consumption on the risk of hepatocellular carcinoma across different age groups: A nationwide cohort study

In this nationwide cohort of 3,869,084 adults, heavy alcohol consumption was associated with increased HCC risk in the 40–59-years and ≥60-years age groups, with the strongest association and highest 10-year cumulative risk observed among heavy drinkers aged ≥60 years.

Mi Na Kim, Kyungdo Han, Dong Yun Kim et al. · JHEP Reports · 0 citations